|
US2005131739A1
|
|
Methods for monitoring severity of panic attacks and other rapidly evolving medical events in real time
|
|
US2006032496A1
|
|
Inhalation actuated percussive ignition system
|
|
WO2005014090A1
|
|
Methods of determining film thicknesses for an aerosol delivery article
|
|
US2004234914A1
|
|
Percussively ignited or electrically ingnited self-contained heating unit and drug-supply unit employing same
|
|
US2004105818A1
|
|
Diuretic aerosols and methods of making and using them
|
|
AU2003239433A1
|
|
Delivery of drug amines through an inhalation route
|
|
AU2002361742A1
|
|
Parental analgesic formulations comprising fentanyl and a cannabinoid receptor agonist
|
|
EP1446102A1
|
|
Delivery of caffeine through an inhalation route
|
|
EP1455875A2
|
|
Open-celled substrates for drug delivery
|
|
WO03037307A1
|
|
Volatilization of a drug from an inclusion complex
|
|
WO02094240A1
|
|
Delivery of physiologically active compounds through an inhalation route
|
|
WO02094246A2
|
|
Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
|
|
WO02094243A1
|
|
Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route
|
|
WO02094242A1
|
|
Delivery of rizatriptan or zolmitriptan through an inhalation route
|
|
WO02094234A1
|
|
Delivery of opioids through an inhalation route
|
|
EP1392260A2
|
|
Delivery of benzodiazepines through an inhalation route
|
|
WO02094239A1
|
|
Delivery of diphenhydramine through an inhalation route
|
|
WO02094235A1
|
|
Delivery of compounds for the treatment of parkinsons through an inhalation route
|
|
WO02094237A1
|
|
Delivery of beta-blockers through an inhalation route
|
|
WO02094238A1
|
|
Delivery of anti-migraine compounds through an inhalation route
|
